Monotherapy of metastatic breast cancer: A review of newer agents

Oncologist

Volumn 4, Issue 1, 1999, Pages 17-33

  Vogel, Charles L ^a,c   Nabholtz, Jean Marc ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c FACP   (United States)

Author keywords

Breast neoplasms; Docetaxel; Paclitaxel; Review; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EDATREXATE; FLUOROURACIL; GEMCITABINE; LOSOXANTRONE; NAVELBINE; PACLITAXEL; PEMETREXED; RALTITREXED; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0033061808     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-1-17     Document Type: Review

References (220)

1. Greenspan EM, Fieber M, Lesnick G et al. Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating agent, thio-TEPA. J Mt Sinai Hosp 1963;30:246-267.
2. Cooper RG. Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 1969;10:15a.
3. Canellos GP, DeVita VT, Gold GL et al. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1974;1:218-220.
4. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52:2127-2137.
5. Ahmann DL, Bisel HF, Eagan RT et al. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 1974;58:877-882.
6. Stuart-Harris RC, Smith IE. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. Cancer Chemother Pharmacol 1982;8:179-182.
7. Brambilla C, Rossi A, Bonfante V et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986;70:261-266.
8. Lippman ME. Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three? Breast Cancer Res Treat 1983;3:117-127.
9. Hortobagyi GN, Buzdar AU, Bodey GP et al. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 1987;5:178-184.
10. Honig SF. Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M et al., eds. Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers, 1996:669-734.
11. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805.
12. Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M et al., eds. Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers, 1996:751-768.
13. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988;6:1368-1376.
14. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-1879.
15. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992;10:657-670.
16. Canellos GP. High dose therapy: here to stay or just visiting? J Clin Oncol 1994;12:5-6.
17. Kennedy MJ. High-dose chemotherapy of breast cancer: is the question answered? J Clin Oncol 1995;13:2477-2479.
18. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-2489.
19. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrobule agent. J Natl Cancer Inst 1990;82:1247-1259.
20. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
21. Reichman BS, Seidman AD, Crown JP et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-1951.
22. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of Taxol: an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
23. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC et al., eds. Breast Disease. Philadelphia: Lippincott, 1991:604-665.
24. Mamounas E, Brown A, Smith R et al. Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-hour infusion of high-dose Taxol. Proc Am Soc Clin Oncol 1998;17:101a.
25. Mamounas E, Brown A, Fisher B et al. 3-hour (hr) high-dose Taxol (T) infusion in advanced breast cancer (ABC): an NSABP Phase II study. Proc Am Soc Clin Oncol 1995;14:127a.
26. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
27. Sledge GW, Neuberg D, Ingle J et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxombicin + paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 1997;16:1a.
28. Kaufman PA, Harris R, Skillings J et al. Losoxantrone + paclitaxel versus paclitaxel alone as first line chemotherapy for metastatic breast cancer (MBC): final results of a phase III randomized trial. Proc Am Soc Clin Oncol 1998;17:124a.
29. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
30. Swain S, Honig S, Walton L. Phase II trial of paclitaxel (Taxol®) as first line chemotherapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995;14:132a.
31. 2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1996;15:128a.
32. Bishop JF, Dewar J, Tattersall MHN et al. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 1997;16:153a.
33. Gamucci T, Piccart M, Brüning P et al. Single agent Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC). Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 1998;17:111a.
34. Peretz T, Sulkes A, Chollet P et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 1995;31(suppl 5):S75a.
35. Seidman AD, Reichman BS, Crown JP et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline exposure. J Clin Oncol 1995;13:1152-1159.
36. Vermorken J, ten Bokkel Huinink WW, Mandjes IAM et al. High-dose paclitaxel in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Centre trial. Semin Oncol 1995;22(suppl 8):16-22.
37. Winer E, Berry D, Duggan E et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Am Soc Clin Oncol 1998;17:101a.
38. Holmes FA, Valero V, Buzdar AU et al. Final results: randomized Phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pts) with met breast cancer (MBC). The long and short of it. Proc Am Soc Clin Oncol 1998;17:110a.
39. Geyer CE Jr, Green SJ, Moinpour C et al. A phase II trial of paclitaxel in patients with metastatic refractory carcinoma of the breast: a Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 1996;15:107a.
40. Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hr infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-1175.
41. Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13:2056-2065.
42. Cognetti F, Aloe A, Nardi M et al. Low activity of paclitaxel (PT) in patients with metastatic breast cancer (MBC) resistant to anthracyclines (A). Proc Am Soc Clin Oncol 1996;15:140a.
43. Dieras V, Marty M, Tubiana N et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 1995;22(suppl 8):33-39.
44. O'Reilly SM, Moiseyenko V, Talbot DC et al. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 1998;17:163a.
45. Wilson WH, Berg SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-1629.
46. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-1884.
47. Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules. Cancer 1994;74:1377-1382.
48. Seidman AD, Murphy B, Hudis C et al. Activity of Taxol® (T) by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study. Proc Am Soc Clin Oncol 1997;16:148a.
49. Seidman AD, Hudis CA, Raptis G et al. Paclitaxel for breast cancer the Memorial Sloan-Kettering Cancer Center experience. Oncology 1997;11(suppl 2):20-28.
50. Sikov W, Akerley W, Strenger R et al. Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC). Proc Am Soc Clin Oncol 1998;17:112a.
51. Asbury R, Chang A, Boros L et al. Weekly moderate-dose paclitaxel (P) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1998;17:127a.
52. Sola C, Lluch A, García-Conde J et al. Phase II study of weekly paclitaxel (P) in recurrent breast cancer after high-dose chemotherapy (HDC). Proc Am Soc Clin Oncol 1998;17:174a.
53. Fellous A, Ohayon R, Vacassin T et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 1989;16(suppl 4):9-14.
54. Canobbio L, Boccardo F, Pastorino G et al. Phase-II study of Navelbine® in advanced breast cancer. Semin Oncol 1989;16(suppl 4):33-36.
55. Garcia-Conde J, Lluch A, Martin M et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-857.
56. Twelves CJ, Dobbs NA, Curnow A et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70:990-993.
57. Bruno S, Puerto VL, Mickiewicz E et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: the Latin-American experience. Am J Clin Oncol 1995;18:392-396.
58. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine as first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
59. Romero A, Rabinovich MG, Vallejo CT et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-341.
60. Vogel C, O'Rourke M, Winer E et al. A clinical trial of intravenous (IV) Navelbine (NVB) (vinorelbine tartrate) for first line treatment of women ≥60 years of age with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1996;15:101a.
61. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-2730.
62. Ranuzzi M, Nisticò C, Garufi C et al. Vinorelbine (VNR) in weekly schedule with G-CSF in patients with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1996;15:125a.
63. Toussaint C, Izzo J, Spielmann M et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-2112.
64. Gasparini G, Caffo O, Barni S et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994;12:2094-2101.
65. Alvarez A, Mickiewicz E, Caceres V et al. Vinorelbine (NVB) activity in heavily pretreated breast cancer (BC) patients (PTS). Proc Am Soc Clin Oncol 1996;15:146a.
66. Extra J-M, Leandri S, Dieras V et al. Phase II study of vinorelbine in first and second-line treatment of advanced breast cancer, Navelbine update and new trends. Ed P Solal Celigny, John Libby Eurotext 1991:213-220.
67. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-1400.
68. Degardin M, Bonneterre J, Hecquet B et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-426.
69. Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567-2574.
70. Robertson JF, Williams MR, Todd J et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace®) therapy. Eur J Cancer Clin Oncol 1989;25:469-475.
71. Howell A, Mackintosh J, Jones M et al. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-1572.
72. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 1995;22:707-710.
73. Hainsworth JD, Greco FA. Phase I trial of weekly docetaxel in patients with advanced refractory cancer. Breast Cancer Res Treat 1997;46:59a.
74. Löffler TM, Freund W, Dröge C et al. Activity of weekly Taxotere® (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:113a.
75. Ibrahim NK, Willey J, Rahman Z et al. Phase II study of vinorelbine (VNR) by 96-hour (H) continuous infusion (CI) for patients (PTS) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1998;17:113a.
76. Buonadonna A, Crivellari D, Frustaci S et al. Vinorelbine (VRL) as palliative treatment in elderly patients with metastatic breast cancer. Breast Cancer Res Treat 1997;46:96a.
77. Vogel CL, O'Rourke M, Weber B et al. The safety of IV Navelbine® in elderly patients with advanced breast cancer (ABC). Breast Cancer Res Treat 1994;32:36a.
78. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
79. Bissery MC, Nohynek G, Sanderink GJ et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs 1995;6:339-355, 363-368.
80. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-2655.
81. Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-322.
82. Fumoleau P, Chevallier B, Kerbrat P et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165-171.
83. Krakowski I, Rios M, Fumoleau P et al. Phase II first line chemotherapy (CT) study with docetaxel (Taxotere®) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1995;14:97a.
84. Trudeau ME, Eisenhauer EA, Higgins BP et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996;14:422-428.
85. Chan S, Friedrichs K, Noël D et al. A randomized phase III study of Taxotere® (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen. Proc Am Soc Clin Oncol 1997;16;154a.
86. Hudis CA, Seidman AD, Crown JP et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
87. Dieras V, Fumoleau P, Chevalier B et al. Second EORTC clinical screening group phase II trial of Taxotere (docetaxel) as first-line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 1994;13:78a.
88. Ravdin PM, Burris HA III, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
89. Bonneterre J, Roche H, Monnier A et al. Taxotere® (TXT) versus 5-fluorouracil + Navelbine® (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results). Proc Am Soc Clin Oncol 1997;16:162a.
90. Vorobiof DA, Chasen MR, Moeken R. Phase II trial of single agent docetaxel in previously treated patients (pts) with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1996;15:130a.
91. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
92. Terzoli E, Nisticò C, Garufi C et al. Docetaxel in advanced breast carcinoma (MBC) patients (PTS) pre-treated with anthracyclines. Proc Am Soc Clin Oncol 1998;17:177a.
93. Sjöström J, Mouridsen H, Pluzanska A et al. Taxotere (T) versus methotrexate-5 fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc Am Soc Clin Oncol 1998;17:111a.
94. Vici P, Conti F, Di Lauro L et al. Single-agent docetaxel as salvage treatment in anthracycline-refractory breast cancer patients. Proc Am Soc Clin Oncol 1998;17:179a.
95. VanOosteram AT, Dieras V, Tubianna-Hulin M et al. Taxotere® (T) in previously treated patients (PTS) with metastatic breast carcinoma (MBC): stratification for anthracycline resistance (AR). Proc Am Soc Clin Oncol 1996;15:141a.
96. Nabholtz JM, Thuerlimann B, Beswoda WR et al. Taxotere® (T) improves survival over mitomycin C vinblastine (MV) in patients (PTS) with metastatic breast cancer (MBC) who have failed an anthracycline (ANT) containing regimen: final results of a phase III randomized trial. Proc Am Soc Clin Oncol 1998;17:101a.
97. Taguchi T, Adachi I, Enomoto K et al. Docetaxel (RP56976) in advanced or recurrent breast cancer: early and late phase II clinical studies in Japan. Proc Am Soc Clin Oncol 1994;13:87a.
98. Piccart MJ, Klijn J, Paridaens R et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-3155.
99. Tominaga S, Suzumura N. Activity of Taxotere® (T) in Japanese patients with anthracycline-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1998;17:178a.
100. Trandafir L, Chahine A, Spielman N et al. Efficacy of Taxotere (TXT) in advanced breast cancer (ABC) patients (PTS) not eligible for further anthracyclines (ANT). Proc Am Soc Clin Oncol 1996;15:105a.
101. Alexandre J, Misset JL, Viens P et al. Antitumoral efficacy of Taxotere® (TX) in women with anthracycline (ANT) mitoxantrone (MX) resistant (ARD) or contraindicated (ANTC) advanced breast cancer (ABC) from the French Extended Access Program. Proc Am Soc Clin Oncol 1997;16:157a.
102. Leonard RCF, O'Brien M, Barrett-Lee P et al. Analysis of covariance of 331 advanced breast cancer cases for factors predictive of response to Taxotere®. Proc Am Soc Clin Oncol 1997;16:147a.
103. Valero V, Burris HA III, Jones SE et al. Multicenter pilot study of Taxotere in taxol-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1996;15:107a.
104. Klink-Alakl M, Riva A, Bruno R et al. Taxotere® (T) safety profile in patients (pts) with liver metastases with or without impaired liver function. Proc Am Soc Clin Oncol 1997;16:220a.
105. Pujade-Lauraine E, Brun B, Maurel A et al. Pathophysiology and management of docetaxel-induced fluid retention. Proc Am Soc Clin Oncol 1996;15:166a.
106. Ravdin P, Valero V, Nabholtz J-M et al. Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere® induced fluid retention. Proc Am Soc Clin Oncol 1996;15:115a.
107. Riva A, Fumoleau P, Roché H et al. Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (pts) treated with Taxotere® (T). Proc Am Soc Clin Oncol 1997;16:188a.
108. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
109. Gianni L, Capri G, Tarenzi E et al. Efficacy and cardiac effects of 3-H paclitaxel (P) plus bolus doxorubicin (DOX) in women with untreated metastatic breast carcinoma. Proc Am Soc Clin Oncol 1996;15:116a.
110. Dombemowsky P, Gehl J, Boesgaard M et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996;23(suppl 11):23-27.
111. Amadori D, Frassineti GL. Doxorubicin and paclitaxel (sequential combination) in the treatment of breast cancer. Oncology 1997;11(suppl 3):30-33.
112. Schwartsmann G, Mans DR, Menke CH et al. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology 1997;11(suppl 3):24-29.
113. Nabholtz J-M, Mackey JR, Smylie M et al. Phase II study of Taxotere (docetaxel), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997;16:148a.
114. Bozec I, Nabholtz J-M, Dieras V et al. Docetaxel (D) in combination with doxorubicin (Dx) (AT) and with cyclophosphamide (CTX) (TAC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC): high activity and absence of cardiotoxicity. Proc Am Soc Clin Oncol 1997;16:163a.
115. Henderson IC, Berry D, Demetri G et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (D) dose level in the adjuvant chemotherapy of patients (pts) with node positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998;17:101a (abstract 390).
116. Holmes FA, Madden T, Neuman RA et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713-2721.
117. Moore MR, Srinivasiah J, Feinberg BA et al. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCl liposome injection (Doxil®) plus paclitaxel (DT) in metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:160a.
118. Ojeda B, Lluch A, Barnadas A et al. A multicenter phase II study of escalating doses of paclitaxel in combination with a fixed dose of doxorubicin as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:163a.
119. Gianni L, Dombernowsky P, Sledge G et al. Cardiac function following combination therapy with Taxol® (T) and doxorubicin (A) for advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1998;17:115a.
120. Gianni L, Viganò L, Locatelli A. Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc Am Soc Clin Oncol 1997;16:224a.
121. Jaremtchuk A, Matwiejuk M, Polera O et al. Feasibility study of the combination Navelbine® (N) and paclitaxel (PCL) in advanced breast cancer (ABC). Proc Am Soc. Clin Oncol 1997;16:175a.
122. Romero Acuña L, Langhi M, Pérez J et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997;16:188a.
123. Weiselberg L, Budman DR, O'Mara V. Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc Am Soc Clin Oncol 1996;15:97a.
124. Fumoleau P, Delecroix V, Perrocheau G et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in PTS with metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol 1996;15:142a.
125. Botto HG, Botto ME, Otegui ML et al. Taxotere (TXT) vs vinorelbine and taxol (VIN-TAX) in patients (PTS) with metastatic breast cancer (MBC) anthracycline resistance. Proc Am Soc Clin Oncol 1998;17:130a.
126. Culine S, Roch I, Pinguet F. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in patients with anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:135a.
127. Deplanque G, Duclos B, Limqacher JM et al. Doxorubicin, docetaxel and vinorelbine (ATN) with G-CSF support in the treatment of metastatic breast cancer (MBC): a pilot study. Proc Am Soc Clin Oncol 1998;17:138a.
128. Ellis GK, Gralow JR, Pierce HI et al. Paclitaxel/vinorelbine (TV) chemotherapy with concurrent G-CSF for metastatic breast cancer (MBC): phase I-II study in doxorubicin-treated patients (PTS). Proc Am Soc Clin Oncol 1998;17:138a.
129. Escudero P, Bueso P, Mayordomo JI et al. Doxetaxel + vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer. Results of a phase II trial. Proc Am Soc Clin Oncol 1998;17:139a.
130. Gardin G, Pronzato P, Tognoni A et al. A phase II trial of vinorelbine (V) and paclitaxel (P) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline containing chemotherapy. Proc Am Soc Clin Oncol 1998;17:142a.
131. Martin M, Garcia Carbonerao I, Lluch A et al. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Proc Am Soc Clin Oncol 1998;17:158a.
132. Romero Acuña L, Langhi M, Pérez J et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol 1998;17:171a.
133. Vogel CL, Penta JS, Hohneker JA. Navelbine® (vinorelbine tartrate) combination chemotherapy for advanced breast cancer. Cancer Invest 1995;14:4445a.
134. Norris B, Pritchard K, James K et al. A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC). a National Cancer Institute of Canada study. Proc Am Soc Clin Oncol 1996;15:98a.
135. Vorobiof D, Goedhals L, Barnardt P et al. Phase II study of IV Navelbine® (NVB) and doxorubicin (DOX) in previously untreated advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997;16:197a.
136. Nisticò C, Garufi C, Pace R et al. Weekly epirubicin (EPI) and vinorelbine (VNR) plus G-CSF in metastatic breast cancer (MBC): high activity with a 75% survival rate at two years. Proc Am Soc Clin Oncol 1997;16:185a.
137. Nisticò C, de Matteis A, Valenza R et al. Epirubicin (EPI) and vinorelbine (VNR): a new promising combination for primary systemic chemotherapy for breast cancer patients (PTS). Proc Am Soc Clin Oncol 1998;17:162a.
138. Tabiadon D, Zonato C, Frontini L et al. Multicentric phase II study with vinorelbine (VNB) and epirubicin (EPI) as first line chemotherapy in metastatic breast cancer (MBC). Preliminary data. Proc Am Soc Clin Oncol 1998;17:176a.
139. Vogel CL. Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. Semin Oncol 1995;22(suppl 5):61-65.
140. Namer M, Soler-Michel P, Turpin F et al. Prospective randomized study comparing mitoxantrone (M) and vinorelbine (V) with fluorouracil (F), epirubicin (E) or Adriamycin® (A) and cyclophosphamide (C) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1997;16:149a.
141. Ramirez MR, Marcom PK, Sutton LM et al. A phase I/II study of Doxil and vinorelbine in metastatic breast cancer patients. Proc Am Soc Clin Oncol 1998;17:169a.
142. Vogel CL, Hochster H, Blumenreich M et al. A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1995;14:91a.
143. Dieras V, Pierga J-Y, Extra J-M et al. Results of a combination of Navelbine (NVB) and Fluoro-Uracil (FU) in advanced breast cancer (ABC) with a group sequential design (GSD). Ann Oncol 1992;3(suppl 5):46a.
144. Nolè F, de Braud F, Munzone E et al. Phase I/II study of vinorelbine (VRLB) in combination with 5-fluorouracil and folinic acid (FUFA) in metastatic breast cancer. Proc Am Soc Clin Oncol 1997;16:185a.
145. Anderson N, Lokich J, Bern M et al. Continuous venous infusion 5-fluororacil [CVI-FU] with weekly vinorelbine [V] in chemoresistant metastatic breast cancer [MBC]: a pilot study. Proc Am Soc Clin Onc 1998;17:126a.
146. Krajnik G, Mohn-Staudner A, Marhold F et al. Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. Proc Am Soc Clin Oncol 1997;16:206a.
147. Rodier JM, Chouaki N, Schlumberger M et al. Gemcitabine (GEM) and vinorelbine (VNB) in solid tumors. Preliminary results of a phase I study. Proc Am Soc Clin Oncol 1997;16:249a.
148. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98a.
149. Northfelt DW. Liposomal anthracycline chemotherapy in the treatment of AIDS-related Kaposi's sarcoma. Oncology 1997;11(suppl 11):21-32.
150. Stewart S, Harrington KJ. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors. Oncology 1997;11(suppl 11):33-37.
151. Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997;11(suppl 11):11-20.
152. Alberts DS, Garcia DJ. A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies. Oncology 1997;11(suppl 11):54-62.
153. Gabizon A, Uziely B, Lotem M et al. Doxil® in patients with pretreated metastatic breast cancer (MBC): a dose-schedule finding study with pharmacokinetics. Proc Am Soc Clin Oncol 1997;16:147a.
154. Jahanzeb M, Frankel C, Elkersh M et al. Rationale for trials studying pegylated liposomal doxorubicin in metastatic breast cancer. Oncology 1997;11(suppl 11):45-53.
155. Lyass O, Uziely B, Heching NI et al. Doxil® in metastatic breast cancer (MBC) after prior chemotherapy: therapeutic results in two consecutive studies. Proc Am Soc Clin Oncol 1998;17:156a.
156. Ranson MR, Carmichael J, O'Byrne K et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-3191.
157. Holder L, Overmoyer B, Silverman P et al. Doxil® and oral cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): preliminary results of a pilot trial. Proc Am Soc Clin Oncol 1998;17:146a.
158. Malik UR, Sparano JA, Wolffe A. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (PTS) with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1998;17:175a.
159. Harris L, Winer E, Batist G et al. Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma. Proc Am Soc Clin Oncol 1998;17:124a.
160. Batist G, Winer E, Navari R et al. Decreased cardiac toxicity by TLC D-99 (liposomal encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma (MBC). Proc Am Soc Clin Oncol 1998;17:115a.
161. Isaksson E, Wilking N, Molin C et al. Phase I trial of DaunoXome and Taxol as first line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:148a.
162. Judson IR. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin Oncol 1992;19:687-694.
163. Leopold WR, Nelson JM, Plowman J et al. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res 1985;45:5532-5539.
164. Vandenberg T, ten Bokkel Huinink W, Hedley D et al. A phase II study of DUP 941 in advanced breast cancer (CA) patients with no prior chemotherapy. Proc Am Soc Clin Oncol 1993;12:67a.
165. Talbot DC, Smith IE, Mansi JL et al. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. J Clin Oncol 1991;9:2141-2147.
166. Smith I, Goldstein L, Wheeler R et al. A phase II study of DUP 941 in advanced breast cancer (CA) patients treated with prior chemotherapy. Proc Am Soc Clin Oncol 1993;12:67a.
167. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-1531.
168. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-4422.
169. Plunkett W, Huang P, Searcy CE et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(suppl 10):3-15.
170. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-2736.
171. Blackstein M, Vogel CL, Ambinder R et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 1997;33(suppl 8):S149a.
172. Possinger K, Kaufmann M, Helsing M et al. Advanced breast cancer: a phase II trial with gemcitabine (gem). Eur J Cancer 1995;31(suppl 5):S80a.
173. Spielmann M, Kalla S, Llombart-Cussac A et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regimens. Eur J Cancer 1997;33(suppl 8):S149a.
174. Possinger K. Gemcitabine in advanced breast cancer. Anti-Cancer Drugs 1995;6(suppl 6):55-59.
175. Conte PF, Bengala C, Danesi R et al. Gemcitabine, epirubicin and paclitaxel (GET) in metastatic breast cancer (MBC): preliminary report of a phase I/II study with pharmacokinetic and peripheral blood progenitor cell (PBPC) mobilization assessment. Proc Am Soc Clin Oncol 1998;17:134a (abstract 511).
176. Delecroix V, Diéras V, Viens P et al. Gemzar® and epirubicin (EP) in patients with metastatic breast cancer (MBC): preliminary results of a phase I study. Proc Am Soc Clin Oncol 1998;17:136a.
177. Mavroudis D, Kouroussis C, Malamos N et al. A phase II trial of docetaxel and gemcitabine as second line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:158a.
178. Nagourney RA, Link J, Kunkel L et al. Phase II trial of cisplatin (Cddp) and gemcitabine (dfdc) in heavily pretreated breast cancer. Proc Am Soc Clin Oncol 1998;17:161a.
179. Garcia Conde J, Lluch A, Pérez Manga G et al. Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study. Proc Am Soc Clin Oncol 1997;16:147a.
180. Mori A, Bertoglio S, Guglielmi A et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993;33:179-180.
181. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899.
182. Chang AY, Most C, Pandya KJ. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 1989;12:453-455.
183. Jabboury K, Holmes FA, Hortobagyi G. 5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989;64:793-797.
184. Lokich J, Anderson NR. Infusional chemotherapy for breast cancer. The Cancer Center of Boston. J-Infus Chemother 1993;3:9-14.
185. Anderson NR. A reappraisal of optimal delivery in advanced breast cancer. J Infus Chemother 1993;3:41-48.
186. Twelves C, Budman DR, Creaven PJ et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 1996;15:476a.
187. Ishikawa T, Utoh M, Sawada N et al. Xeloda™ (capecitabine): an orally available tumor-selective fluoro-pyrimidine carbarnate. Proc Am Soc Clin Oncol 1997;16:208a.
188. Schüller J, Cassidy J, Reigner BG et al. Tumor selectivity of Xeloda™ in colorectal cancer patients. Proc Am Soc Clin Oncol 1997;16:227a.
189. Blum JL, Buzdar AU, LoRusso PM et al. A multicenter phase II trial of Xeloda™ (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1998;17:125a.
190. O'Shaughnessy J, Moiseyenko V, Bell D et al. A randomized phase II study of Xeloda (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥55 years. Proc Am Soc Clin Oncol 1998;17:103a.
191. Khoury P, Villalona-Calero M, Blum J et al. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:206a (abstract 793).
192. Pronk L, Vasey AP, Sparreboom A et al. A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of Xeloda™ plus Taxotere™. Proc Am Soc Clin Oncol 1998;17:212a.
193. Brade WP, Hendrich K. Tegafur: a review of pharmacology and toxicology. Contr Oncol 1983;14:2-25.
194. Bedikian AY, Bodey GP, Valdivieso M et al. Phase I evaluation of oral tegafur. Cancer Treat Rep 1983;67:81-84.
195. Nakazato H, Koike A, Sail S et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: a prospective randomized clinical trial. Proc Am Soc Clin Oncol 1997;16:279a.
196. Cao S, Durrani FA, Maue R et al. Modulation of the antitumor activity of ftorafur (Ft) and uracil (U)-Ft combination (UFt) in rats bearing advanced colon carcinoma. Proc Am Soc Clin Oncol 1993;12:212a.
197. Pazdur R, Covington WP, Brown NS et al. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Am Soc Clin Oncol 1996;15:474a.
198. Ansfield FJ, Kallas GJ, Sigson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983;1:107-110.
199. Marsoni S, Hoth D, Simon R et al. Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat Rep 1987;71:71-80.
200. Wada T, Koyama H, Terasawa T. Recent advances in chemotherapy for advanced breast cancer. Recent Results Cancer Res 1981;76:316-324.
201. Kajanti MJ, Pyrhonen SO, Maiche AG. Oral tegafur in the treatment of metastatic breast cancer: a phase II study. Eur J Cancer 1993;29A:863-866.
202. Sole LA, Albanell J, Bellmunt J et al. Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer 1995;75:831-835.
203. Daniels M, Diaz-Rubio E, Guillem V et al. Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 1993;23:363-365.
204. Villalon AH, De Gùzman LB, Samson MCLC. Tegafur+uracil (UFT)-doxorubicin-cyclophosphamide vs 5FU-doxorubicin-cyclophosphamide in advanced breast cancer: a randomized trial. Proc Am Soc Ciln Oncol 1996;15:139a.
205. Martin M, Casado A, Lopez-Martin JA et al. Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. Oncology 1997;11(suppl 10):83-85.
206. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993;46:2243-2248.
207. Baccanari DP, Davis ST, Knick VC et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993;90:11064-11068.
208. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-1510.
209. Rivera E, Chevlen E, Eckardt J et al. A phase II open-label study to evaluate a 28-day oral regimen of 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with taxane and anthracycline resistant advanced breast cancer: preliminary results. Proc Am Soc Clin Oncol 1998;17:113a.
210. Lind MJ, Smith IE, Coleman RE et al. Phase II study of MTA (LY231514) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC). Proc Am Soc Clin Oncol 1998;17:112a.
211. Schmid FA, Sirotnak FM, Otter GM et al. New folate analogs of the 10-deaza-aminopterin series: markedly increased activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985;69:551-553.
212. Sirotnak FM, Schmid FA, Samuels LL et al. 10-Ethyl-10-deazaaminopterin: structural design and biochemical, pharmacologic, and antitumor properties. NCI Monogr 1987;5:127-131.
213. Chou TC, Otter GM, Sirotnak FM. Schedule-dependent synergism of taxol or Taxotere® with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 1996;37:222-228.
214. Schornagel JH, van der Vegt S, Verweij J et al. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol 1992;3:549-552.
215. Vandenberg TA, Pritchard KI, Eisenhauer EA et al. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1993;11:1241-1244.
216. Slichenmyer WJ, Rowinsky EK, Donehower RC et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291.
217. Bonneterre J, Pion JM, Adenis A et al. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 1993;12:94a.
218. Spaeth D, Bonneterre J, Marty M et al. Phase II studies of two trial regimens of topotecan as second-line, single agent therapy in advanced breast cancer. Proc Am Soc Clin Oncol 1997;16:192a.
219. Goldschmidt E, Bonneterre J, Fumoleau P et al. A phase II study of topotecan on a daily x 5 schedule as second-line single agent therapy in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1997;16:171a.
220. Cobleigh MA, Vogel CL, Tripathy D et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:97a.